BioVisioN and Abbott sign research agreement

Published: 12-Sep-2005

German biotech company BioVisioN has signed an agreement with Abbott to collaborate on research relating to the discovery of novel biomarkers for lung cancer.


German biotech company BioVisioN has signed an agreement with Abbott to collaborate on research relating to the discovery of novel biomarkers for lung cancer.

According to the agreement, BioVisioN will analyse biological samples provided by Abbott to discover tumor biomarkers. Under the agreement, BioVisioN will receive research payments and, if successful, milestones and royalty payments.

'Our early activities in the area of proteomics and peptidomics are now paying off,' said Dr Rainer Voegeli, chief business officer of BioVisioN. 'We are proud that Abbott has chosen us as a partner.'

BioVisioN specialises in the identification of disease-relevant peptides and proteins using peptidomics and differential peptide display.

You may also like